Eli Lilly Licenses Camurus’ FluidCrystal Technology to Advance Long-Acting Incretin Products
Shots:
- Camurus has granted Eli Lilly exclusive global rights to research, develop, manufacture, & commercialize long-acting incretin drugs using Camurus’ FluidCrystal tech for cardiometabolic diseases
- As per the deal, Camurus will receive ~$290M in upfront, development & regulatory milestones as well as $580M in sales-based milestones & global net sales-based tiered royalties in mid-single digits
- Agreement incl. up to 4 Lilly proprietary drugs, selected from dual GIP & GLP-1 receptor agonists, triple GIP, glucagon & GLP-1 receptors agonist, with an option to incl. amylin receptor agonists
Ref: PRNewswire | Image: Eli Lilly and Camurus | Press Release
Related News:- Rznomics Partners with Eli Lilly for RNA Editing Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com